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Abstract
Spinal muscular atrophy (SMA), a leading genetic cause of infant death worldwide,
is an autosomal recessive disorder caused by the loss of SMN1 (survival motor
neuron 1), which encodes the protein SMN. The loss of SMN1 causes a deficiency
in SMN protein levels leading to motor neuron cell death in the anterior horn of the
spinal cord. SMN2, however, can also produce some functional SMN to partially
compensate for loss of SMN1 in SMA suggesting increasing transcription of SMN2
as a potential therapy to treat patients with SMA. A cAMP response element was
identified on the SMN2 promoter, implicating cAMP activation as a step in the
transcription of SMN2. Therefore, we investigated the effects of modulating the
cAMP signaling cascade on SMN production in vitro and in silico. SMA patient
fibroblasts were treated with the cAMP signaling modulators rolipram, salbutamol,
dbcAMP, epinephrine and forskolin. All of the modulators tested were able to
increase gem formation, a marker for SMN protein in the nucleus, in a dose-
dependent manner. We then derived two possible mathematical models simulating
the regulation of SMN2 expression by cAMP signaling. Both models fit well with our
experimental data. In silico treatment of SMA fibroblasts simultaneously with two
different cAMP modulators resulted in an additive increase in gem formation. This
study shows how a systems biology approach can be used to develop potential
therapeutic targets for treating SMA.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive, neurodegenerative
disorder characterized by the progressive loss of a-motor neurons in the anterior
horn of the spinal cord; this loss leads to progressive muscle weakness and atrophy
[1]. SMA is a leading genetic cause of infant death worldwide with 1 in 5000–
10,000 children born with the disease [2, 3]. Loss of or mutation in SMN1
(survival motor neuron 1) leads to SMA [4]. In humans and only in humans,
SMN1 is duplicated to yield SMN2 [5, 6]. There is a single nucleotide change
(CRT) within SMN2 exon 7 that causes most of SMN2 mRNAs to lack exon 7
(SMND7). The resultant SMND7 protein is unstable and not fully functional
[7, 8]. SMN2 can, however, provide some full-length, functional SMN (FL-SMN)
protein. The number of SMN2 copies modifies disease severity in SMA patients
[9–16]. In transgenic mouse models for SMA, the copy number of human SMN2
modulates the phenotypic severity [17–19]. SMN2 is, therefore, an endogenous
genetic modifier of disease severity in SMA.
Because of this phenotype modifying property, SMN2 has been the target for
numerous drug discovery strategies. Targeting cyclic adenosine monophosphate
(cAMP) signaling is of particular interest in developing inducers of SMN2
expression. The cAMP signaling cascade (Fig. 1) is used by both prokaryotes and
eukaryotes to regulate various processes including cell growth, metabolism and
stress response [20]. The SMN2 promoter contains at least one cAMP-response
element (CRE) that is able to bind to activated CRE-binding protein (phospho-
CREB) [21]. The b2-adrenergic agonist salbutamol increases the amount of FL-
SMN protein in SMA fibroblasts and leukocytes of SMA patients [22, 23].
Forskolin, which stimulates adenylyl cyclase (AC) catalysis to produce cAMP from
ATP, increases SMN2 promoter activity [21]. The synthetic analogue dibutyryl
cAMP (dbcAMP)—which activates cyclic AMP-dependent protein kinase
(PKA)—also increases SMN2 promoter activity [21]. Taken together, these studies
show that modulation of cAMP signaling can increase SMN expression from
SMN2.
In this study, we will examine the effect of modulating cAMP signaling on SMN
expression in SMA cells using a systems biology approach. cAMP signaling will be
regulated by one of four possible targets (Fig. 1): activation of G protein-coupled
receptors, activation of AC, activation of PKA and inhibition of phosphodies-
terases (PDEs) that break down cAMP. Within the nuclei of most eukaryotic cells,
SMN protein localizes to discreet foci known as gems, or gemini of coiled bodies
[24]. The number of gems are markedly reduced within the nuclei of cells from
SMA patients [9]. Using gem formation as an indicator of the expression of
functional, FL-SMN protein, we will develop computational models of
interactions between the cAMP pathway and gem formation to investigate how
modulating cAMP signaling dynamics affects FL-SMN production. This systems
biology approach consists of a synergistic interaction between experimental data
and mathematical models. The experimental data and domain knowledge are used
to develop the initial models and through a process of iteration, the model
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assumptions are updated to come up with an improved model [25]. Such a
systems modeling approach can ultimately aid in the development and
optimization of cAMP signaling-based therapeutic strategies for SMA.
Materials and Methods
Fibroblast Cell Culture
GM03813 fibroblasts [26] (Coriell Cell Repositories; Camden, NJ) were derived
from a SMA patient with deletion of SMN1 and 2 copies of SMN2. GM03814
fibroblasts [26] (Coriell Cell Repositories) were derived from the carrier mother of
GM03813; this line, therefore, carries 1 copy of SMN1. All fibroblast lines were
maintained in Dulbecco’s modified essential medium (DMEM; Life Technologies,
Grand Island, NY) containing 10% fetal bovine serum (FBS; Atlas Biologicals,
Fort Collins, CO), 2 mM L-glutamine (Life Technologies) and 1% penicillin/
streptomycin (Life Technologies).
Drug Treatment
Cells were seeded onto gelatinized glass coverslips at a density of 4000 cells/cm2.
Cells were treated with one of the following compounds (n53/dose): dbcAMP (5–
Fig. 1. The cAMP pathway and SMN2 expression. In this signaling cascade, ligand activation of the
membrane bound G protein-coupled receptors such as the b-adrenergic receptor (bAR) results in the
dissociation of the Ga,s subunit from the receptor. Ga,s then activates adenylyl cyclase (AC). Once stimulated,
AC produces cAMP by cyclizing intracellular ATP. cAMP then activates a serine/threonine kinase known as
cAMP-dependent protein kinase—or protein kinase A (PKA). The regulatory subunits of PKA are then
released and the catalytic subunit acts on many downstream targets including the cAMP-response element-
binding (CREB) protein. Phosphorylated CREB (phospho-CREB) binds to cAMP response elements (CREs)
with the promoter regions of various genes including SMN2. cAMP signaling is attenuated by cyclic nucleotide
phosphodiesterases (PDEs) which break down cAMP into AMP.
doi:10.1371/journal.pone.0115473.g001
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500 mM; EMD Millipore, Billerica, MA), epinephrine (1–100 nM; Sigma-Aldrich,
St. Louis, MO), forskolin (0.5–50 mM; EMD Millipore), salbutamol (1–100 nM;
Sigma-Aldrich), rolipram (0.1–10 mM; Sigma-Aldrich) or vehicle. ddH2O was
utilized as the vehicle for the dbcAMP treatments while DMSO was the vehicle for
the remaining compounds. Test compounds were added to the medium at a
1:1000 dilution. Medium was changed daily and fresh compound was added for 5
days.
Immunofluorescence
Immunostaining of fibroblast cells was accomplished as described previously [27].
Briefly, cells grown on gelatinized coverslips were fixed with Fixative Buffer (2%
paraformaldehyde, 400 mM CaCl2, 50 mM sucrose in 100 mM sodium phosphate
buffer, pH 7.4) for 30 min at room temperature, thoroughly rinsed with
phosphate-buffered saline (PBS) and permeabilized with ice-cold acetone for
10 min. After drying for at least 30 min at room temperature, the cells were
rehydrated with PBS for 10 min at room temperature and then blocked with
56BLOCK for 60 min at room temperature. The cells were incubated overnight
with primary antibody solution (mouse anti-SMN mAb (MANSMA2 (8F7);
Developmental Studies Hybridoma Bank, Iowa City, IA [28]) diluted 1:200 in
16BLOCK) at 4 C˚. The cells were then washed extensively (3610 min) with PBS
and incubated with secondary antibody solution (biotinylated goat anti-mouse
IgG (Jackson ImmunoResearch) diluted 1:400 with 16BLOCK) for 60 min at
room temperature. The cells were then washed with PBS (3610 min) and then
incubated with AlexaFluor 594-conjugated streptavidin (Life Technologies)
diluted 1:200 with PBS for 60 min at room temperature. Cells were then
counterstained with Hoescht 33342 (1 mg/mL; Life Technologies) in PBS for
5 min. After thorough washing with PBS, coverslips were mounted onto glass
slides with ImmuMount (Shandon Lipshaw) and stored at 4 C˚ until analysis.
Gem Count Analysis
SMN immunostaining in fibroblasts was visualized using a DMRXA2 epifluor-
escence microscope (Leica Microsystems) with an ORCA-ER cooled camera
(Hamamatsu, Hamamatsu City, Japan) and Volocity 6.1.1 software (Perkin-
Elmer). For gem counting, the following parameters were measured in 100
randomly selected nuclei: the number of gems, the number of cells with gems and
the number of cells with more than 1 gem. The gem counts were converted into a
concentration value (in mM) using an approximate average cell volume
(2.68610213 L). This conversion assumes that all cells are of equal volume [29].
Development of Mathematical Models
The computational model was visualized and developed in CellDesigner [30].
Each model was then converted into Systems Biology Markup Language (SBML)
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format [31] and imported into MATLAB using SBToolbox [32]. SBToolbox was
used to complete parameter sensitivity and model simulations.
Simplified cAMP Model
Model Derivation
In order to adapt the Williamson model [33] to our system, their parameters
required reworking to be in accordance with the units of our data. The
Williamson model was shown to match data from literature [34, 35] which is
reported in units of nmol per gram wet weight versus minutes. Through careful
inspection, the time units of the model were determined to be 20 seconds (s) (i.e.
one time unit represents 20 s in the data) with the concentration units remaining
the same as the data. The data points of the model results presented in Williamson
were extracted using WebPlotDigitizer v.2.6 (http://arohatgi.info/
WebPlotDigitizer) and converted into the proper units.
Our simplified model consists of three ordinary differential equations (ODEs;
Equations 1–3) and two conservation equations (Equations 4 & 5). Equation 1
represents the rate of change in the active form of the G protein receptor (GPa) in
the presence or absence of a stimulatory hormone or agonist. Equation 2 models
the instantaneous changes in active PKA (PKAa) as a result of cAMP production.
Equation 3 captures both cAMP production from ATP by AC and degradation
into AMP via PKAa-stimulated PDE activity. The conservation equations
demonstrate the balance between the active and inactive forms of both GP and
PKA.
In order to further simplify the system, the two PDE terms from the
Williamson et al. model [33] were combined into one term. As evinced in the
Williamson et al. study [33], PDE2 does not have a significant effect on cAMP
concentration, especially when compared to PDE1. Since there are multiple
isoforms of PDEs in humans [36], we generated a general PDE term to model the
overall inhibitory action of PDEs in the cells. The model parameters were defined
as in [33] and their descriptions are summarized in Table 1.
d½GPa
dt
~kf (½totalGP{½GPa½Hormone{kr½GPa ð1Þ
d½PKAa
dt
~kf (½totalPKA{½PKAa)½cAMP{kr½PKAa ð2Þ
d½cAMP
dt
~
ACbasalzkA½GPa
1zKi½PKAa {
½PKAaVmaxPDE½cAMP
KMPDEz½cAMP ð3Þ
½totalGP~½GPaz½GPi ð4Þ
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½totalPKA~½PKAaz½PKAi ð5Þ
The model was then fit to the converted experimental data using the
optimization algorithms detailed below. The optimized parameters determined
from this model fitting are listed in Table 1.
The experimental data utilized by Williamson et al. [33] represented
concentration in units of nmol per gram wet weight (gww). However, the glucose
pulse used in this study was in units of mM. In order to convert the data into mM
concentrations, the following equation was used:
C(nM)~
c(nmol=gww)cw
(1000nmol=mmol)Vc
ð6Þ
where C(nM) is concentration of cAMP in milimolar, Cw is the conversion factor
to grams dry weight (0.15) and Vc is the volume of 10
7 cells (2.6861026 L;
approximately 107 cells in 1 gww). The equation and constant values were adapted
from the equation detailed in Williamson et al. [33].
Table 1. Optimized parameter values for cAMP pathway full cAMP:SMN2 model.
Parameter Description Value Units Source
GP kf G-Protein Activation Rate 1.33610
27 (mMmin)21 This Work
GP kr G-Protein Deactivation Rate 2.05610
27 min21 This Work*
PKA kf PKA Activation Rate 5.37 (mMmin)
21 This Work*
PKA kr PKA Deactivation Rate 0.65 min
21 This Work*
ACbasal Base AC Activation Rate 1.00610
25 mM/min This Work*
GP ka G-Protein Catalysis Rate 87.83 min
21 This Work*
PKA Ki PKA Inhibition Rate 1419.09 mM
21 This Work*
VmaxPDE Max cAMP Degradation Rate 1.75 min
21 This Work
KmPDE PDE Dissociation Rate Constant 7.79 mM This Work
CREB kf CREB Phosphorylation Rate 59.54 (mMmin)
21 This Work
CREB kr CREB De-phosphorylation Rate 0.93 min
21 This Work
kmax Max Transcription Rate 1.14610
25 mM/min This Work
c Promoter Binding Efficiency 8.6161023 mM21 This Work
dm mRNA Degradation Rate Constant 2.10610
23 min21 [56]
H Hill Coefficient 1 n/a This Work
kp Translation Rate Constant 9109.61 min
21 This Work
dp FL-SMN Degradation Rate Constant 2.70610
23 min21 [39]
kg Gem Formation Rate Constant 3.07610
26 min21 This Work
dg Gem Degradation Rate Constant 7.70610
24 min21 [39]
Fka Forskolin Catalysis Rate Constant 0.027 min
21 This Work
a Salbutamol Splicing Constant 7172.40 mM21 This Work
KI Rolipram Inhibition Constant 1.71610
25 mM This Work
The parameters marked with an asterisk (*) were carried over from the simplified cAMP model.
doi:10.1371/journal.pone.0115473.t001
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Parameter estimation
Parameters for the base model were estimated by fitting our modified model to
the data extracted from the Williamson results through a simulated annealing
algorithm [37, 38], which is efficient at finding the global minimum for
optimization. The algorithms were taken from Systems Biology Toolbox
(SBToolbox) [32] in MATLAB and the estimation was run using the
SBparameterestimation function from SBToolbox as well as the main estimation
functions listed in additional files.
Full cAMP:SMN2 Model
Model Development
In order to capture the treatment pathway of interest, the downstream effectors of
the base model were incorporated to develop a model of how the cAMP pathway
affects FL-SMN protein production and gem formation. Our full cAMP pathway
model encompasses the base model equations with four additional ODEs
(Equations 7–10) and one additional conservation equation (Equation 11). ODEs
were derived for CREB phosphorylation by PKAa (Equation 7), SMN2 promotion
by phospho-CREB (Equation 8), translation of FL-SMN mRNA into FL-SMN
protein (Equation 9) and the self-assembly of FL-SMN into gems (Equation 10).
SMN2 activation was modeled using the Hill equation while the rest of the
parameters were based on mass action kinetics. The conservation relationship
detailed in Equation 11 represents the total CREB molecules in the cell. Each
model parameter is defined in Table 1. Our model used units of min for time and
mM for concentration.
d½CREBp
dt
~kf (½totalCREB{½CREBp)½PKAa{kr½CREBp ð7Þ
d½SMN2mRNA
dt
~
kmax(c½CREBp)H
1z(c½CREBp)H
{dm½SMN2mRNA{kp½SMN2mRNA ð8Þ
d½FLSMN
dt
~kp½SMN2mRNA{kg ½FLSMN{dp½FLSMN ð9Þ
d½Gem
dt
~kg ½FLSMN{dg ½Gem ð10Þ
½totalCREB~½CREBpz½CREB ð11Þ
Mathematical Modeling, cAMP Signaling and SMA
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Both salbutamol and epinephrine directly activate G proteins by binding with
their receptors outside the cell. In our model, both compounds were directly
substituted for the hormone concentration term in Equation 1:
½Hormone~½Salbutamol~½Epinepherine ð12Þ
In addition to activating the SMN2 promoter, salbutamol also alters the splicing
of SMN2 mRNA causing an increase in FL-SMN production over SMND7 [22].
The interaction of salbutamol with the splicing machinery was modeled as
proportional increase in the transcription rate of SMN2 mRNA given in Equation
8:
Transcriptionrate~
kmax(1za½Salbutamol)(c½CREBp)H
1z(c½CREBp)H
ð13Þ
Treatments with the AC activator forskolin were modeled as an increase in
basal AC activity proportional to the dosage of forskolin:
ACbasal
~ACbasalzFka½Forskolin ð14Þ
For the treatments with dbcAMP, the dose concentration was added directly to
the existing cAMP concentration in the system:
½cAMP~½cAMPz½dbcAMP ð15Þ
Rolipram is a well-known PDE inhibitor, which indirectly causes an increase in
cAMP. The inhibition interaction was modeled as reversible and competitive in
Michaelis-Menten kinetics. The presence of the inhibitor alters the apparent
Michaelis constant for the binding of cAMP to PDE:
KappM PDE~KMPDE(1z
½R
Ki
) ð16Þ
where [R] represents the concentration of rolipram and Ki represents the inhibitor
dissociation constant.
Parameter Estimation
Since the gem count data was collected after a treatment window of 5 days, the
concentrations were treated as steady state values for the system. The steady state
assumption allowed the model equations to be set to zero and solved for their
constituent model states giving a system of algebraic equations. Due to the highly
conserved nature of the cAMP pathway, the parameter values derived from the
base model were carried over in order to reduce the parameter space to be
optimized. A system of equations was derived through the steady state assumption
on the full cAMP:SMN2 model.
Mathematical Modeling, cAMP Signaling and SMA
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The full cAMP:SMN2 model equations were solved for their principal model
states (Equations 17–23). To eliminate the inter-dependence of cAMP and PKAa,
the cAMP variable was solved to give an equation for cAMP in terms of PKA
(Equation 18) where Y represents the numerator of the AC term. This equation
was then substituted into Equation 19 and solved for PKA using the equation
solver in MATLAB (S1 Document).
½GPssa ~
kf (½Sz½E)½GPt
krzkf (½Sz½E) ð17Þ
½cAMPss~ YK
app
m
KiVmPDE½PKAssa zVmPDE½PKAssa {Y
ð18Þ
½PKAssa ~
kf ½cAMPss
krzkf ½cAMPss ½PKAt ð19Þ
½CREBssp ~
kf ½PKSAssa 
krzkf ½PKAssa 
½CREBt ð20Þ
½SMN2mRNAss~ kmax(1za½Salbutamol)(c½CREB
ss
p )H
(dmzkp)(1z(c½CREBssp )H)
ð21Þ
½FLSMNss~ kp
kgzdp
½SMN2mRNAss ð22Þ
½Gemss~ kg
dg
½FLSMNss ð23Þ
Parameter estimation was completed through a sign squared error (SSE)
analysis between the gem steady state concentrations derived from the gem count
data and the full cAMP:SMN2 model calculations for each compound and dose.
The parameter space was covered by generating a multidimensional matrix
encompassing the possible combinations of parameter values over a specified
range for each parameter to be estimated. For an easier model fit, the two controls
were assumed to be identical and their data was averaged together.
Mathematical Modeling, cAMP Signaling and SMA
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Alternate cAMP:SMN2 Model
Model Development
An alternate pathway has been suggested in the literature [39] which shows active
PKA directly stimulating the self-assembly of SMN into gems. Gems are much
more stable than monomeric SMN so increasing the gem formation rate would
increase the overall SMN concentration over time. Burnett et al. also found no
noticeable increase in SMN mRNA levels coinciding with increased PKAa levels
suggesting that transcription is not involved. In order to examine the implications
of the alternate pathway, a new model was developed by modifying our full
cAMP:SMN2 model.
Equations 1, 2 and 3 from the full cAMP:SMN2 model were also used for this
model. The key modifications made were the elimination of the CREB and
transcription terms, simplification of translation to a constant rate, T, and the
addition of PKAa concentration to the gem formation term. The elimination of
the CREB term also allowed for removal of the related conservation equation form
the model. The alternate cAMP:SMN2 model parameters are defined in Table 3.
d½FLSMN
dt
~T{kg ½PKAa½FLSMN{dp½FLSMN ð24Þ
d½Gem
dt
~kg ½PKAa½FLSMN{dg ½Gem ð25Þ
½totalGP~½GPaz½GPi ð26Þ
½totalPKA~½PKAaz½PKAi ð27Þ
The modifications made for each of the compounds were identical to the full
cAMP:SMN2 model, except that the effect of salbutamol on splicing was
represented as a proportional increase in the translation rate (Equation 28):
T~T(1za½Salbutamol) ð28Þ
Parameter Estimation
Parameter optimization for the alternate cAMP:SMN2 model was completed
using the steady state SSE analysis described earlier. The G protein, cAMP and
PKA steady state equations were carried over from the full cAMP:SMN2 model
and the FL-SMN (Equation 29) and gem (Equation 30) state equations were
derived accordingly.
½FLSMNss~T(1za½Salbutamol)
kg ½PKAssa zdp
ð29Þ
Mathematical Modeling, cAMP Signaling and SMA
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½Gemss~ kg
dg
½FLSMNss½PKAssa  ð30Þ
Sensitivity Analysis
Steady state sensitivity analysis was completed according to the following
equation:
Snij~
Xssi(pjzDpj){Xssi(pj)
Dpj
 pj
Xssi(pj)
ð31Þ
where Snij is the normalized sensitivity of species i with respect to parameter j, Xssi
is species i at steady state, pj is parameter j, and Dpj is the change in parameter j.
The sensitivities of gem concentration and FL-SMN concentration to changes in
each of the system parameters were calculated.
Table 2. Normalized local sensitivity of gem concentration to full cAMP:SMN2 model parameters.
Parameter Sensitivity
H 23.9461023
GP ka 1.54610
25
PKA kf 1.36610
25
dm 1.31610
25
kmax 1.22610
25
PKA kr 1.19610
25
a 21.0361025
kg 27.08610
26
FkA 6.86610
26
GP kr 6.70610
26
dp 6.50610
26
CREB kf 5.98610
26
VmaxPDE 25.63610
26
c 5.3661026
PKA ki 4.84610
26
CREB kr 4.50610
26
ACbasal 4.36610
26
KI 22.7361026
kp 2.33610
26
GP kf 1.98610
26
dg 21.97610
26
KmPDE 21.53610
26
doi:10.1371/journal.pone.0115473.t002
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PLOS ONE | DOI:10.1371/journal.pone.0115473 December 16, 2014 11 / 26
Statistical Analysis
All quantitative data were expressed as mean ¡ standard error. Comparisons
made between quantitative data were made using one-way ANOVA with a
Bonferonni post hoc test. A p-value less than or equal to 0.05 was considered
statistically significant. Statistical analyses of quantitative data were completed
using SPSS v.22.
Results
Effect of Modulating cAMP Signaling on Gem Localization in SMA
Fibroblasts
Fibroblasts derived from a type II SMA patient (GM03813; [26]) were treated with
increasing doses (n53/dose) of one of the following modulators of cAMP
signaling: epinephrine, salbutamol, forskolin, dbcAMP and rolipram. Fig. 1 shows
how each compound modulates cAMP signaling. All 5 of the cAMP signaling
modulators tested increased SMN immunostaining in the nucleus as well as in the
cytosol of SMA fibroblasts (Fig. 2). Further analysis of SMN localization to gems
showed that all 5 of the cAMP signaling modulators increased the number of gems
in 100 randomly selected nuclei (Fig. 3A), the proportion of cells containing gems
(Fig. 3B) and proportion of cells containing multiple gems (Fig. 3C) in a dose-
dependent manner relative to vehicle-treated SMA fibroblasts. While none of the
compounds attained gem counts similar to those observed in fibroblasts
(GM03814) derived from the mother of GM03813—i.e. carrier fibroblasts, the
number of gems/100 nuclei in SMA fibroblasts treated with the highest doses of
dbcAMP, forskolin, salbutamol and rolipram reached at least 50% of the gem
counts found in carrier fibroblasts.
Development of a Computational Model for the Effect of cAMP
Signaling on SMN2 Expression
We developed a computational model of cAMP signaling in humans by modifying
a previously published model of the cAMP pathway in yeast [33]. Because of the
highly conserved nature of cAMP signaling, essential features of the cAMP
pathway are common between humans and yeast and can be modeled with
limited changes between species. The original model in yeast consists of 3 ordinary
differential equations (ODEs) and 16 parameters [33] (Fig. 4A). By modeling
only those functions essential to cAMP and likely conserved between yeast and
humans, our base model of the cAMP pathway contained 3 differential equations
and 8 parameters (Fig. 4B). Even with this simplified model, we were able to
capture the essential dynamics of cAMP signaling reported previously [33]
(Fig. 4C). Therefore, our computational model represents an essential set of
relationships that are likely at work in humans and clinically relevant.
We then extended this simplified model of cAMP signaling to include
production of FL-SMN through CREB and SMN2 (Fig. 5A). We also added
Mathematical Modeling, cAMP Signaling and SMA
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pathways through which treatments to modify cAMP levels may affect FL-SMN
production. We used the number of gems/100 nuclei as our experimental
dataset—after being converted to concentration (S1 Table)—to determine how
well our model fits with observed data. Except for those found in the literature,
the parameters between cAMP production and gem formation within the
computational model were fit to these experimental data by minimizing the sum
of squared error (SSE) between simulation and experiment. After preliminary
simulation, select parameters from the base equations were optimized to better
capture the dynamics observed in the human system (Table 1). By comparing
model simulations to our experimental data, we can predict which treatments act
through the pathways we proposed. The full cAMP:SMN2 model accurately
predicted the response of SMA fibroblasts to treatments with forskolin (Fig. 5B),
dbcAMP (Fig. 5C), and rolipram (Fig. 5D). Therefore, it is likely that the overall
effects of these drugs act through the cAMP signaling cascade as modeled. Both
epinephrine (Fig. 5E) and salbutamol (Fig. 5F) treatments, however, showed
deviations from model predictions. The full cAMP:SMN2 model predicted a
nearly linear, dose-dependent increase in gem formation while the data predicted
a sharp increase in gem formation followed by a plateau. The data suggest
saturation of the G protein-coupled receptors that bind both epinephrine and
salbutamol. These compounds may act through additional, cAMP-independent
pathways to give their full effect on gem formation or may have additional levels
of regulation that were not simulated.
Having built and tested a computational model of FL-SMN production, we
next used a local sensitivity analysis to identify which targets in the cAMP
signaling pathway may be most beneficial to optimally increase FL-SMN
Fig. 2. The effect of cAMP signaling modulators on SMN localization to gems. SMN immunostaining
(red) of GM03813 SMA fibroblasts treated for 5 days with (A) 500 mM dbcAMP, (B) ddH2O (vehicle for A), (C)
100 nM epinephrine, (D) 50 mM forskolin, (E) 100 nM salbutamol, (F) 10 mM rolipram or (G) DMSO (vehicle for
C-F). (H) SMN immunostaining of GM03814 carrier fibroblasts. The nuclei were counterstained with Hoescht
33342 (blue). Scale bar, 13 mm.
doi:10.1371/journal.pone.0115473.g002
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Fig. 3. The effects of cAMP signaling modulators on gem counts in SMA fibroblasts. GM03813 SMA
fibroblasts were treated with differing doses of dbcAMP, epinephrine, forskolin, salbutamol or rolipram for 5
days (n53/dose/drug). The concentrations for each dose of each drug (in mM) are shown below the
appropriate bars of each graph. The vehicle for dbcAMP is ddH2O (black bars) while DMSO (grey) serves as
Mathematical Modeling, cAMP Signaling and SMA
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vehicle for the remaining compounds. The number of SMN-positive nuclear gems was counted in 100
randomly selected nuclei. Gem count analysis was also completed in GM03814 carrier fibroblasts so as to
compare the gem data in treated SMA fibroblasts to those observed in healthy cells. The gem count analysis
was expressed as (A) the number of gems per 100 nuclei, (B) the proportion of cells containing gems and (C)
the proportion of cells containing multiple gems. The asterisk (*) denotes a statistically significant (p#0.05)
difference between drug-treated cells and vehicle (either ddH2O for dbcAMP or DMSO for epinephrine,
forskolin, salbutamol or rolipram)-treated cells.
doi:10.1371/journal.pone.0115473.g003
Fig. 4. Development of the simplified cAMP:SMN2model. Simplified cAMP model captures essential functions of cAMP signaling. (A) The original cAMP
model generated by Williamson et al. [33]. (B) Simplified cAMP model. (C) Predicted concentrations of activated G proteins (GPa; blue lines), activated PKA
(PKAa; green lines) and cAMP (red lines) following addition of glucose. The solid lines represent the predictions based on the simplified cAMP model while
the dashed lines represent data points obtained from [34, 35].
doi:10.1371/journal.pone.0115473.g004
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Fig. 5. Development of the full cAMP:SMN2 model. Final gem concentrations of full cAMP:SMN2 model (A) simulations (open squares) compared to
experimental data (closed circles) for varying concentrations of forskolin (B), dbcAMP (C), rolipram (D), epinephrine (E) and salbutamol (F).
doi:10.1371/journal.pone.0115473.g005
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production and gem formation. Gem concentrations at steady-state were used as
output measures to identify the sensitivities of FL-SMN production to
perturbations in each model parameter (Table 2). The Hill coefficient for the
binding of phospho-CREB to the CRE present in the SMN2 promoter had the
most impact on the final gem concentration in the full cAMP:SMN2 model. Since
the Hill coefficient affects the rate of SMN2 transcription, the sensitivity analysis
suggests that the transcription of SMN2 has the greater impact on cAMP
signaling-induced gem formation and functional, FL-SMN expression.
Using Full cAMP:SMN2 Mathematical Model to Predict the Effects
of Combination Treatments on SMN2 Expression
As previously discussed, the full cAMP:SMN2 model accurately predicts the effects
of treatment by rolipram, forskolin and dbcAMP. We used the full cAMP:SMN2
model to examine the effect of a simultaneous treatment with two of these three
compounds: rolipram + dbcAMP, forskolin + dbcAMP and rolipram + forskolin.
All three combinations demonstrated synergistic responses yielding higher steady-
state gem concentrations with each increasing dose. However, both combinations
with dbcAMP hit a maximum gem concentration around 6.0 pM (Figs. 6A and
6B) while the combination of rolipram and forskolin peaks around 6.7 pM
(Fig. 6C). Since the gem concentration in carrier fibroblasts is approximately 7.0
pM (S1 Table), these results suggest that manipulation of the cAMP signaling
pathway at multiple points in the cascade can optimally increase SMN2
expression.
Table 3. Optimized parameter values for cAMP pathway alternate cAMP:SMN2 model.
Parameter Description Value Units Source
GP kf G-Protein Activation Rate 1.33610
27 (mMmin)21 This Work
GP kr G-Protein Deactivation Rate 2.05610
27 min21 This Work*
PKA kf PKA Activation Rate 5.37 (mMmin)
21 This Work*
PKA kr PKA Deactivation Rate 0.65 min
21 This Work*
ACbasal Base AC Activation Rate 1.00610
25 mM/min This Work*
GP ka G-Protein Catalysis Rate 87.83 min
21 This Work*
PKA KI PKA Inhibition Rate 1419.09 mM
21 This Work*
Vm Max cAMP Degradation Rate 9.56 min
21 This Work
Km PDE Dissociation Rate Constant 6.66 mM This Work
T Transcription Rate 5.42610212 mM/min This Work
dp FL-SMN Degradation Rate Constant 2.70610
23 min21 [39]
kg Gem Formation Rate Constant 0.38 min
21 This Work
dg Gem Degradation Rate Constant 7.70610
24 min21 [39]
Fka Forskolin Catalysis Rate Constant 0.05 mM
21 This Work
a Salbutamol Splicing Constant 5149.72 mM21 This Work
The parameters marked with an asterisk (*) were carried over from the simplified cAMP model.
doi:10.1371/journal.pone.0115473.t003
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Fig. 6. Simulated treatments of SMA fibroblasts with two different cAMP modulators. Dual dose
simulation data for the combination treatments with forskolin and dbcAMP (A), rolipram and dbcAMP (B) and
forskolin and rolipram (C).
doi:10.1371/journal.pone.0115473.g006
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Development of an Alternate Model for the Effect of cAMP
Signaling on SMN2 Expression
Previous work has shown that activation of PKA directly affects gem formation
independent of SMN2 transcription [39]. Based on this observation, we also
developed an alternate model of the interplay between cAMP signaling and the
expression of functional FL-SMN and gem formation (the alternate cAMP:SMN2
model; Fig. 7A). We fit the alternate cAMP:SMN2 model to the available gem
concentration data (S1 Table) as described for the full cAMP:SMN2 model. The
downstream parameters as well as select simplified model parameters were
included for optimization (Table 3). Similar to the full cAMP:SMN2 model, the
alternate cAMP:SMN2 model predicted responses due to treatments with
forskolin (Fig. 7B), dbcAMP (Fig. 7C) and rolipram (Fig. 7D); the alternate
cAMP:SMN2 model also yielded deviations for salbutamol (Fig. 7E) and
epinephrine (Fig. 7F) treatments.
With the alternate cAMP:SMN2 model fully optimized, we conducted a
normalized local sensitivity analysis in order to reveal the interactions most
important for gem production within the alternate pathway. The alternate
cAMP:SMN2 model sensitivity results show that both the gem formation and
degradation rates have a significant influence on final gem concentration, as
would be expected (Table 4). Furthermore, their sensitivities are three orders of
magnitude greater than the corresponding sensitivity to the Hill coefficient in the
full cAMP:SMN2 model. The estimated gem formation rate for the alternate
cAMP:SMN2 model is approximately five orders of magnitude larger than that of
the full cAMP:SMN2 model, thus making this parameter the key differentiator
between the two proposed cAMP:SMN2 models.
We also developed and analyzed a combination model which encompasses the
effects of cAMP signaling on the upregulation of SMN2 promoter activity and
transcription (the full cAMP:SMN2 model) as well as the direct stimulation of
gem formation by PKA (the alternate cAMP:SMN2 model). The fit of this
combination cAMP:SMN2 model to the experimental data, however, was
significantly weaker than for the fits of either the full cAMP:SMN2 and alternate
cAMP:SMN2 models (data not shown). Therefore, this combinatorial effect of
cAMP signaling on the expression of functional SMN2 is far less likely to be
biologically accurate.
Discussion
In this study, we use a systems biology approach with mathematical models to
characterize the regulation of SMN2 expression by cAMP signaling. This is the
first time, to our knowledge, that a systems biology approach has been used to
develop SMA therapeutic strategies. We focused on the interaction between cAMP
signaling and SMN2 expression in this study since there is ample evidence in the
literature showing that induction of cAMP signaling increases SMN2 expression
[21–23]. The cAMP signaling treatment data were used to generate two distinct
Mathematical Modeling, cAMP Signaling and SMA
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Fig. 7. Development of the alternate cAMP:SMN2 model. Final gem concentrations of alternate cAMP:SMN2 model (A) simulations (open squares)
compared to experimental data (closed circles) for varying concentrations of forskolin (B), dbcAMP (C), rolipram (D), epinephrine (E) and salbutamol (F).
doi:10.1371/journal.pone.0115473.g007
Mathematical Modeling, cAMP Signaling and SMA
PLOS ONE | DOI:10.1371/journal.pone.0115473 December 16, 2014 20 / 26
mathematical models—full cAMP:SMN2 and alternate cAMP:SMN2 models—for
the interaction of cAMP signaling and SMN2 expression. Simulated data from
both models match very well with experimental data suggesting that either model
is robust. The mathematical models can also be used to predict the effects of drug
combinations on cAMP-mediated regulation of SMN2 expression. This study will
also guide future investigations into the mechanisms by which cAMP signaling
regulated SMN2 expression.
Gem formation serves as an indicator of the expression of fully functional, FL-
SMN protein in this study. Reduced gem formation correlates with SMN protein
expression and disease severity in fibroblasts derived from SMA patients [9].
Numerous studies have identified drug compounds that increase the number of
gems in SMA patient cells [27, 40–49]. In these studies, drug-induced changes in
gem formation are verified by corresponding changes in SMN protein levels in
SMA fibroblasts measured by immunoblot or enzyme-linked immunosorbent
assays (ELISAs). Some of these gem inducers also increase SMN protein levels in
the central nervous system and can ameliorate the phenotype in SMA mouse
models [47, 50–52]. These observations support the rationale for using gem
formation as an indicator of SMN expression in our mathematical models.
Activation of cAMP signaling increases SMN2 expression but there is debate as
to how this signaling cascade regulates SMN2. Some groups report that the
regulation of SMN2 promoter activity and mRNA transcription are influenced by
cAMP signaling [21–23] but others suggest that the regulation of SMN2
expression by cAMP signaling occurs post-transcriptionally, i.e. by influencing
FL-SMN protein stability [39]. The two mathematical models generated in this
study for the interaction between cAMP signaling and SMN2 expression—full
Table 4. Normalized local sensitivity of gem concentration to alternate cAMP:SMN2 model parameters.
Parameter Sensitivity
kg 1.00
dg 20.91
KI 5.78610
24
PKA kf 1.05610
24
PKA kr 21.04610
24
GP kr 4.06610
27
T 3.7961027
GP kf 3.18610
27
a 2.2961027
dp 21.86610
27
GP ka 21.62610
27
FkA 1.3761027
ACbasal 29.77610
27
VmPDE 9.24610
27
PKA Ki 9.05610
27
KmPDE 1.33610
27
doi:10.1371/journal.pone.0115473.t004
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cAMP:SMN2 and alternate cAMP:SMN2 models—differ by whether or not cAMP
signaling affects SMN2 transcription. Either model fit very well with the
experimental data. However, when the two models were combined, the fit with
the experimental data was not strong suggesting that only one model correctly
simulates the interaction between the cAMP signaling cascade and SMN2
expression. At present, we cannot determine which mathematical model more
accurately simulates cAMP signaling-dependent regulation of SMN2. A detailed
examination of the time course of gem formation—as well as other levels of SMN2
regulation—in response to cAMP signaling modulators would permit model
discrimination and refinement.
The regulation of SMN expression by cAMP signaling is complex and multi-
faceted. As a result, some facets of the interaction between cAMP signaling and
SMN gene expression were not included in our mathematical models. For
example, PKA has been shown to directly phosphorylate SMN in vitro [39, 53].
This PKA-dependent phosphorylation of SMN may modulate its interactions with
components of the core SMN:gemins macromolecular complex including gemin-
2 (SIP1), gemin-5 and gemin-8 [39, 53]. Since the effects of PKA phosphorylation
of SMN on its function and localization are not yet known, we could not factor
this variable in our mathematical models. Also, activation of NMDA-type,
glutamatergic receptors increases SMN expression in the spinal cord by AKT-
mediated phosphorylation of CREB and repression of ERK-activated Elk-1
[54, 55]. It remains to be determined whether cAMP signaling-independent
phosphorylation of CREB would affect SMN expression in our model system.
Once we have a better understanding of how these events affect SMN expression
and function, direct PKA phosphorylation of SMN and the intersection of other
signaling pathways—like AKT and MAP kinase (ERK)—can be integrated into
mathematical models of the interactions of cAMP signaling on SMN expression
and function.
In summary, we have demonstrated that increasing cAMP activation increases
FL-SMN production, as measured by gem formation, in human cells using a
systems biology approach, We generated data-driven, mathematical models
describing the interactions between cAMP signaling and functional FL-SMN
production (gem formation) from SMN2. These models can be used to identify
the components of the cAMP signaling cascade that may be most effective at
increasing SMN levels in SMA cells as well as to predict the effects of combination
treatment strategies. Development of cAMP signaling-based therapeutic strategies
using a combination of biological data and mathematical modeling will be
essential for treating SMA.
Supporting Information
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